Novartis' Entresto Blockbuster Status On Track After CHMP Backing
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency recommends that Entresto be granted marketing authorization for the treatment of adults with symptomatic chronic heart failure with reduced ejection fraction.